Aveo On­col­o­gy’s Fo­tiv­da com­bo fails in Phase 3 kid­ney can­cer test

Adding an im­mune check­point in­hibitor did not im­prove the per­for­mance of Aveo On­col­o­gy’s Fo­tiv­da in a late-phase study in cer­tain pa­tients with re­nal cell car­ci­no­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER